FIBER-ML, an Open-Source Supervised Machine Learning Tool for Quantification of Fibrosis in Tissue Sections.


Journal

The American journal of pathology
ISSN: 1525-2191
Titre abrégé: Am J Pathol
Pays: United States
ID NLM: 0370502

Informations de publication

Date de publication:
05 2022
Historique:
received: 09 11 2021
revised: 12 01 2022
accepted: 20 01 2022
pubmed: 21 2 2022
medline: 27 4 2022
entrez: 20 2 2022
Statut: ppublish

Résumé

Pathologic fibrosis is a major hallmark of tissue insult in many chronic diseases. Although the amount of fibrosis is recognized as a direct indicator of the extent of disease, there is no consentaneous method for its quantification in tissue sections. This study tested FIBER-ML, a semi-automated, open-source freeware that uses a machine-learning approach to quantify fibrosis automatically after a short user-controlled learning phase. Fibrosis was quantified in sirius red-stained tissue sections from two fibrogenic animal models: acute stress-induced cardiomyopathy in rats (Takotsubo syndrome-like) and HIV-induced nephropathy in mice (chronic kidney disease). The quantitative results of FIBER-ML software version 1.0 were compared with those of ImageJ in Takotsubo syndrome, and with those of inForm in chronic kidney disease. Intra- and inter-operator and inter-software correlation and agreement were assessed. All correlations were excellent (>0.95) in both data sets. The values of discriminatory power between the pathologic and healthy groups were <10

Identifiants

pubmed: 35183511
pii: S0002-9440(22)00051-7
doi: 10.1016/j.ajpath.2022.01.013
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

783-793

Informations de copyright

Copyright © 2022 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Caterina Facchin (C)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France. Electronic address: caterina.facchin@mail.mcgill.ca.

Anais Certain (A)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

Thulaciga Yoganathan (T)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

Clement Delacroix (C)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

Alicia Arevalo Garcia (AA)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

François Gaillard (F)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

Olivia Lenoir (O)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

Pierre-Louis Tharaux (PL)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France.

Bertrand Tavitian (B)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France; Department of Radiology, Assistance Publique-Hôpitaux de Paris, Hopital Européen Georges Pompidou, Paris, France.

Daniel Balvay (D)

Université de Paris, INSERM, Paris Cardiovascular Research Center, Paris, France; Department of Radiology, Assistance Publique-Hôpitaux de Paris, Hopital Européen Georges Pompidou, Paris, France. Electronic address: daniel.balvay@inserm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH